Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Aerovate Therapeutics Q3 EPS $(0.71) Misses $(0.69) Estimate; Cash, Cash Equivalents And Available-for-sale Securities Of $135.2M Will Be Sufficient To Fund Operations Into 2026

Author: Benzinga Newsdesk | November 13, 2023 09:28am
Aerovate Therapeutics (NASDAQ:AVTE) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate of $(0.69) by 2.9 percent. This is a 26.79 percent decrease over losses of $(0.56) per share from the same period last year.

Posted In: AVTE


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist